Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

1. Quantitative Image Analysis of HER2 Immunohistochemistry for Breast Cancer

Quantitative Image Analysis of HER2 Immunohistochemistry for Breast Cancer CAP Laboratory Improvement Programs Quantitative Image Analysis of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry for Breast Cancer Guideline From the College of American Pathologists Marilyn M. Bui, MD, PhD; Michael W. Riben, MD; Kimberly H. Allison, MD; Elizabeth Chlipala, BS, HTL(ASCP)QIHC; Carol Colasacco, MLIS, SCT(ASCP); Andrea G. Kahn, MD; Christina Lacchetti, MHSc; Anant Madabhushi, PhD; Liron (...) ) immunohistochemistry (IHC) for breast cancer where QIA is used. Design.—The College of American Pathologists (CAP) convened a panel of pathologists, histotechnologists, and computer scientists with expertise in image analysis, immunohistochemistry, quality management, and breast pathology to develop recommendations for QIA of HER2 IHC in breast cancer. A systematic review of the literature was conducted to address 5 key questions. Final recom- mendations were derived from strength of evidence, open comment

2019 College of American Pathologists

2. Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women.

Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women. American College of Radiology End User License Agreement ACR Appropriateness Criteria is a registered trademark of the American College of Radiology. By accessing the ACR Appropriateness Criteria®, you expressly agree and consent to the terms and conditions as described at: http://www.acr.org/~/media/ACR/Documents/AppCriteria/TermsandConditions.pdf Personal use of material (...) Cancer American College of Radiology ACR Appropriateness Criteria ® Clinical Condition: Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women Variant 1: Newly diagnosed. Initial workup. Rule out bone metastases. Radiologic Procedure Rating Comments RRL* FDG-PET/CT whole body 2 ???? Tc-99m bone scan whole body 1 ??? X-ray skeletal survey 1 ??? Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually

2019 American College of Radiology

3. Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines

Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer (...) : Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Last updated: June 11, 2019 Project Number: RB1351-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of 3D digital tomosynthesis with or without 2D mammography compared with 2D mammography alone for breast cancer diagnosis? What is the diagnostic accuracy of 3D digital tomosynthesis with or without 2D mammography compared with 2D mammography alone

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

4. Preoperative Seed Placement for Breast Cancer Surgery: Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Preoperative Seed Placement for Breast Cancer Surgery: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Preoperative Seed Placement for Breast Cancer Surgery: Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Preoperative Seed Placement for Breast Cancer Surgery: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Preoperative Seed Placement for Breast Cancer Surgery: Clinical Effectiveness, Cost-Effectiveness, and Guidelines (...) Last updated: April 1, 2019 Project Number: RB1319-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of preoperative seed placement for patients undergoing surgery for breast cancer? What is the cost-effectiveness of preoperative seed placement for patients undergoing surgery for breast cancer? What are the evidence-based guidelines regarding methods of preoperative tumor localization for patient

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

5. Gene Expression Profiling Tests for Breast Cancer: A Rapid Qualitative Review

Gene Expression Profiling Tests for Breast Cancer: A Rapid Qualitative Review Gene Expression Profiling Tests for Breast Cancer: A Rapid Qualitative Review | CADTH.ca Find the information you need Gene Expression Profiling Tests for Breast Cancer: A Rapid Qualitative Review Gene Expression Profiling Tests for Breast Cancer: A Rapid Qualitative Review Last updated: April 18, 2019 Project Number: RC1099-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical (...) Appraisal Result type: Report Question What are patients’ and clinicians’ expectations of gene expression profiling tests for breast cancer? How do patients and clinicians understand, communicate, and make decisions to undergo gene expression profiling testing for breast cancer? How do patients and clinicians understand, communicate and make decisions based on the results? How does the option, or not, of gene expression profile testing help to shape patients’, and clinicians’ experiences and perceptions

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

6. Trastuzumab Emtansine (Kadcyla) for Early Breast Cancer (EBC) — Details

Trastuzumab Emtansine (Kadcyla) for Early Breast Cancer (EBC) — Details Trastuzumab Emtansine (Kadcyla) for Early Breast Cancer (EBC) — Details | CADTH.ca Find the information you need Trastuzumab Emtansine (Kadcyla) for Early Breast Cancer (EBC) — Details Trastuzumab Emtansine (Kadcyla) for Early Breast Cancer (EBC) — Details Project Number pCODR 10182 Brand Name Kadcyla Generic Name Trastuzumab Emtansine Tumour Type Breast Indication Early Breast Cancer (EBC) Funding Request For the adjuvant (...) treatment of patients with HER2-positive early breast cancer, who have residual disease, after pre-operative systemic treatment. KADCYLA should be continued for 14 cycles or until disease progression or unacceptable toxicity. If KADCYLA is discontinued in the event of toxicity, treatment with trastuzumab may be continued to complete one year of HER2-directed therapy. Review Status Under Review Pre Noc Submission Yes NOC Date Manufacturer Hoffmann-La Roche Limited Sponsor Hoffmann-La Roche Limited

2019 CADTH - Pan Canadian Oncology Drug Review

7. Kisqali (with Fulvestrant) for Advanced or Metastatic Breast Cancer – Details

Kisqali (with Fulvestrant) for Advanced or Metastatic Breast Cancer – Details Kisqali (with Fulvestrant) for Advanced or Metastatic Breast Cancer – Details | CADTH.ca Find the information you need Kisqali (with Fulvestrant) for Advanced or Metastatic Breast Cancer – Details Kisqali (with Fulvestrant) for Advanced or Metastatic Breast Cancer – Details Project Number pCODR 10195 Brand Name Kisqali Generic Name Ribociclib with Fulvestrant Tumour Type Breast Indication Advanced or Metastatic Breast (...) Cancer Funding Request In combination with fulvestrant for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial therapy or following disease progression on endocrine therapy Review Status Under Review Pre Noc Submission Yes NOC Date Manufacturer Novartis Pharmaceuticals Canada Inc. Sponsor Novartis Pharmaceuticals Canada Inc. Submission Date August 26, 2019 Submission Deemed Complete September 10, 2019 Submission Type New Indication

2019 CADTH - Pan Canadian Oncology Drug Review

8. Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines

Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines Last updated: August 27, 2019 Project Number: RB1389-000 Product (...) Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical utility of telemammography for the diagnosis of breast cancer? What is the cost-effectiveness of telemammography for the diagnosis of breast cancer? What are the evidence based guidelines regarding the use of telemammography for the diagnosis of breast cancer? Key Message No relevant health technology assessments, systematic reviews, meta-analyses, randomized-controlled

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

9. Pertuzumab (Perjeta) - HER2-positive early breast cancer

Pertuzumab (Perjeta) - HER2-positive early breast cancer 1 Published 07 October 2019 1 SMC2197 pertuzumab 420mg concentrate solution for infusion (Perjeta®) Roche Products Ltd 06 September 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission considered under the orphan equivalent (...) process pertuzumab (Perjeta®) is not recommended for use within NHSScotland. Indication under review: for use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. The addition of pertuzumab to trastuzumab and chemotherapy improved invasive disease- free survival in patients with HER2-positive early breast cancer at high risk of recurrence. Overall survival data are immature. The submitting

2019 Scottish Medicines Consortium

10. Combination Therapy for the Treatment of Adults with Any Stage Breast Cancer: Clinical Effectiveness and Guidelines

Combination Therapy for the Treatment of Adults with Any Stage Breast Cancer: Clinical Effectiveness and Guidelines Combination Therapy for the Treatment of Adults with Any Stage Breast Cancer: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Combination Therapy for the Treatment of Adults with Any Stage Breast Cancer: Clinical Effectiveness and Guidelines Combination Therapy for the Treatment of Adults with Any Stage Breast Cancer: Clinical Effectiveness (...) and Guidelines Last updated: February 5, 2019 Project Number: RB1307-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of combination therapy in adults with any stage of breast cancer? What are the evidence-based guidelines associated with the use of combination therapy in adults with any stage of breast cancer? Key Message Two systematic reviews (one with a meta-analysis), 15 non-randomized studies, and one

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

11. Sample Selection for Biomarker Testing in Adults with Breast Cancer: Guidelines

Sample Selection for Biomarker Testing in Adults with Breast Cancer: Guidelines Sample Selection for Biomarker Testing in Adults with Breast Cancer: Guidelines | CADTH.ca Find the information you need Sample Selection for Biomarker Testing in Adults with Breast Cancer: Guidelines Sample Selection for Biomarker Testing in Adults with Breast Cancer: Guidelines Last updated: February 6, 2019 Project Number: RB1305-000 Product Line: Research Type: Devices and Systems Report Type: Summary (...) of Abstracts Result type: Report Question What are the evidence-based guidelines regarding sample selection for biomarker testing to inform treatment decisions in adults with breast cancer? Key Message Four evidence-based guidelines were identified regarding sample selection for biomarker testing in adults with breast cancer. Files Rapid Response Summary of Abstracts Published : February 6, 2019 Related Content Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

12. Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review

Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review | CADTH.ca Find the information you need Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review Last updated: May 3, 2019 Project Number: RC1104-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What (...) are the experiences and perspectives of breast cancer patients, their caregivers and their health care providers with respect to breast cancer surgical care in rural areas? To ensure the relevance of the analysis to the objectives of the primary research question, a secondary set of research questions was explored during data extraction and analysis:a) How do people with breast cancer, and their families, experience travelling for breast cancer surgical care?b) What is the meaning and impact of receiving breast

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

13. Intraoperative Mammography for Breast Cancer Surgery: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Intraoperative Mammography for Breast Cancer Surgery: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Intraoperative Mammography for Breast Cancer Surgery: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Intraoperative Mammography for Breast Cancer Surgery: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Intraoperative Mammography for Breast Cancer Surgery: A Review of Clinical (...) Effectiveness, Cost-Effectiveness, and Guidelines Last updated: April 22, 2019 Project Number: RC1102-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of intraoperative imaging with mammography for breast cancer surgery? What is the cost-effectiveness of intraoperative imaging with mammography for breast cancer surgery? What are the evidence-based guidelines regarding intraoperative imaging

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

14. Assessment and management of bone health in women with oestrogen receptor?positive breast cancer receiving endocrine therapy: position statement summary

Assessment and management of bone health in women with oestrogen receptor?positive breast cancer receiving endocrine therapy: position statement summary Assessment and management of bone health in women with oestrogen receptor‐positive breast cancer receiving endocrine therapy: position statement summary | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page (...) doi: 10.5694/mja__.______ Search Reset  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement close Assessment and management of bone health in women with oestrogen receptor‐positive breast cancer receiving endocrine therapy: position statement summary Mathis Grossmann, Sabashini K Ramchand, Frances Milat, Amanda Vincent, Elgene Lim, Mark A Kotowicz, Jill Hicks and Helena J Teede Med J Aust 2019; 211 (5

2019 MJA Clinical Guidelines

15. Abemaciclib (Verzenio) - treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer

Abemaciclib (Verzenio) - treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original

2019 Health Canada - Drug and Health Product Register

16. Baseline Staging Imaging for Distant Metastasis in Women with Stage I, II, and III Breast Cancer

Baseline Staging Imaging for Distant Metastasis in Women with Stage I, II, and III Breast Cancer Guideline 1-14 Version 3 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Baseline Staging Imaging for Distant Metastasis in Women with Stage I, II, and III Breast Cancer A. Arnaout, N. Varela, M. Allarakhia, L. Grimard, A. Hey, J. Lau, L. Thain, A. Eisen, and the Staging in Early Stage Breast Cancer Advisory Committee 1 Report Date: October 7, 2019 (...) (Vancouver Style): Arnaout A, Varela NP, Allarakhia M, Grimard L, Hey A, et al. Baseline staging imaging for distant metastasis in women with stage I, II, and III breast cancer. Toronto (ON): Cancer Care Ontario; 2019 October 7. Program in Evidence- Based Care Guideline No.: 1-14 Version 3. Copyright This report is copyrighted by Cancer Care Ontario; the report and the illustrations herein may not be reproduced without the express written permission of Cancer Care Ontario. Cancer Care Ontario reserves

2019 Cancer Care Ontario

17. Metastatic Breast Cancer Summary

Metastatic Breast Cancer Summary Metastatic breast cancer Breast cancer is the most common cancer diagnosed in Australia. Approximately 5% of patients diagnosed with breast cancer in Australia have metastatic disease at initial breast cancer diagnosis (NCCI, Cancer Australia), and some patients who have early breast cancer at diagnosis will have a recurrence that is metastatic. However exact statistics on patients with metastatic breast cancer in Australia are not currently available (...) . For patients with metastatic breast cancer at diagnosis in Australia, 5-year relative survival is low at 32%, compared with over 95% for patients with early breast cancer. While many patients with metastatic breast cancer are living longer, current treatments for metastatic breast cancer are generally not curative. The main treatment goals for metastatic breast cancer are to effectively manage symptoms and optimise quality of life, as well as to prolong survival. There can be emotional, physical

2019 Cancer Australia

18. Abemaciclib (Verzenio) - Metastatic Breast Cancer

Abemaciclib (Verzenio) - Metastatic Breast Cancer Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf of which you

2019 Health Canada - drugs and medical devices

19. Triptorelin acetate (Decapeptyl) - breast cancer

Triptorelin acetate (Decapeptyl) - breast cancer 1 Published 7 October 2019 1 SMC2186 triptorelin sustained-release 3mg powder for suspension for injection (Decapeptyl SR®) Ipsen Ltd. 06 September 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission triptorelin (Decapeptyl SR ® (...) ) is accepted for use within NHSScotland. Indication under review: As adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in women at high risk of recurrence who are confirmed as premenopausal after completion of chemotherapy. In premenopausal women with early breast cancer at high risk of recurrence, ovarian suppression (provided by triptorelin, oophorectomy or radiation ablation) plus an aromatase inhibitor increased disease free

2019 Scottish Medicines Consortium

20. Sentinel Lymph Node Biopsy for the Management of Breast Cancer: A Review of Guidelines

Sentinel Lymph Node Biopsy for the Management of Breast Cancer: A Review of Guidelines Sentinel Lymph Node Biopsy for the Management of Breast Cancer: A Review of Guidelines | CADTH.ca Find the information you need Sentinel Lymph Node Biopsy for the Management of Breast Cancer: A Review of Guidelines Sentinel Lymph Node Biopsy for the Management of Breast Cancer: A Review of Guidelines Last updated: April 24, 2019 Project Number: RC1103-000 Product Line: Research Type: Devices and Systems (...) Report Type: Summary with Critical Appraisal Result type: Report Question What are the evidence-based guidelines regarding methods for sentinel lymph node biopsy for the management of breast cancer? Key Message Five evidence-based guidelines were identified. SLNB is recommended for axillary staging for patients with early-stage or invasive breast cancer without clinically or pathologically positive lymph nodes. SLNB is recommended in patients with ductal carcinoma in situ (DCIS) when mastectomy

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review